Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

One Step Closer to Personalized Medicine for RA Patients

Carina Stanton  |  May 30, 2018

“This bioassay could give us a method that is easy to adopt in the clinical setting to test a patient’s blood and determine if a therapy is effective long before the [current] months-long period it takes to observe if a therapy is leading to improvement,” he says.

Personalized Rheumatology Care
As he and his research team continue to work to determine more about how inflammatory diseases may be understood at the molecular level through dysregulated gene expression, Dr. Ho sees several important ramifications of this work. He notes that:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Testing for dysregulated PTPN22 will help identify patients at risk for RA who haven’t developed signs found in current laboratory approaches, such as testing positive for anti-cyclic citrullinated peptide antibody;
  2. Uncovering additional genes that are abnormally expressed, such as PTPN22, may help leverage better ways to develop and target therapies with implications for finding a cure; and
  3. Tracking this signature in RA patients may help determine patients who can safely stop therapy.

Dr. Ho believes that “finding this signature of RA gets us closer to identifying the signatures for other inflammatory diseases.” He hopes to identify more of these signatures by studying patients diagnosed with lupus or psoriatic arthritis.


Carina Stanton is a freelance science journalist in Denver.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Chang H-H, Dwivedi N, Nicholas AP, et al. The W620 polymorphism in PTPN22 disrupts its interaction with peptidylarginine deiminase type 4 and enhances citrullination and NETosis. Arthritis Rheum. 2015 Sep;67(9):2323–2334.
  2. Chang H-H, Liu G-Y, Dwivedi N, et al. A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. JCI Insight. 2016 Oct 20;1(17):e90045.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis

Related Articles

    Doest Rheumatoid Arthritis Take a Toll?

    November 15, 2013

    Exploring the Toll background

    Understanding the Role of Citrullination in Rheumatoid Arthritis

    April 28, 2014

    Activation of peptidylarginine deiminases during complement and perforin activity may be at the core of citrullinated autoantigen production in RA.

    Reading Rheum

    December 1, 2007

    Handpicked Reviews of Contemporary Literature

    Multiple Interferons, Including IFNB1, May Play a Role in SLE

    August 14, 2019

    A recent gene expression analysis found an enriched downstream interferon signature, with predominantly IFNB1 signatures in systemic lupus erythematosus (SLE) patients. The study also found lower expression of all downstream interferon signatures in the kidneys of lupus nephritis patients…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences